Tuğba Önder

12PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersMolecular targetsFood properties (incl. characteristics and health benefits)Cancer therapy (excl. chemotherapy and radiation therapy)Midwifery not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 24, 2026
Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.

|Aug 07, 2026
Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer.

|Mar 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek

|Mar 03, 2026
Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.

Tuğba Önder, Öztürk Ateş

|Jun 29, 2025
Factors Affecting Survival in Older Patients on Enteral Nutritional Support.

Tuğba Önder, Çağatay Çavuşoğlu, Ebru Öztürk

|Apr 21, 2025
PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.

Tuğba Önder, İrem Öner, Cengiz Karaçin

Pageof 2

Frequent Collaborators

1 joint publications

Cengiz Karaçin

1 joint publications

İrem Öner

1 joint publications

Bengü Dursun

1 joint publications

Şendağ Yaslıkaya